Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ...

The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment ...

Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of ...

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on ...

UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Just a few months ago, in December 2025, the European Commission and EIB Group announced a new initiative to invest €10 ...

Greenlight Capital, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter ...

On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock.